Quantification of CBFβ/MYH11 fusion transcript by Real Time RT-PCR in patients with INV(16) acute myeloid leukemia

Leukemia

Volumn 15, Issue 7, 2001, Pages 1072-1080

  Marcucci, G ^a   Caligiuri, M A ^a   Dohner H ^b   Archer, K J ^a   Schlenk, R F ^b   Dohner K ^b   Maghraby, E A ^a   Bloomfield, C ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

AML; CBF MYH11; Inv(16); Minimal residual disease; Real time RT PCR

Indexed keywords

ANTINEOPLASTIC AGENT; CORE BINDING FACTOR; DNA BINDING PROTEIN; DNA GLYCOSYLASE MUTY; DNA GLYCOSYLTRANSFERASE; GLYCOSIDASE; HYBRID PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW EXAMINATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHROMOSOME 16; CHROMOSOME 16P; CHROMOSOME 16Q; CHROMOSOME INVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE FUSION; GENETIC TRANSCRIPTION; HIGH RISK PATIENT; HOUSEKEEPING GENE; HUMAN; LEUKEMIA REMISSION; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; ADOLESCENT; FOLLOW UP; GENETICS; MIDDLE AGED;

ADOLESCENT; ADULT; CHROMOSOMES, HUMAN, PAIR 16; DNA GLYCOSYLASES; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INVERSION, CHROMOSOME; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; N-GLYCOSYL HYDROLASES; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION FACTORS;

EID: 0034742483     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402159     Document Type: Article

References (20)

1. Chromosome aberrations in de novo acute myeloid leukemia in adults: Clinical implications
2. Frequency of prolonged remission duration following high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
3. Detection of minimal residual disease in acute myeloid leukaemia: Methodologies, clinical and biological significance
4. Fusion between transcription factor CBFβ/PEBP2b and a myosin heavy chain in acute myeloid leukemia
5. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia
6. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia
7. Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by nested polymerase chain reaction with allele specific amplification
8. Detection of CBFβ/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission
9. Detection of the chromosome 16 CBF beta-MYH11 fusion transcript in myelomonocytic leukemias
10. Detection of CBFbeta/MYH11 fusion transcript in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation
11. Prognosis value of residual disease monitoring by polymerase chain reaction in patients with CBFbeta/MYH11-positive acute myeloblastic leukemia
12. Defining the 'absence' of the CBFβ/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: A call for definitions
13. Detection and quantitation of the CBFbeta/MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML
14. Competitive CBFbeta/MYH11 reverse-transcription polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): A pilot study
15. Detection of the AML1/ETO fusion transcript in patients with t(8;21)-associated AML using a novel 'real time' quantitative RT-PCR assay
16. Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia
17. Real time quantitative PCR
18. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse
19. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia
20. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring